Monoclonal Antibodies targeting EpCAM



Embodiments of the invention provide high affinity recombinant EpCAM-binding antibodies. Methods of using a such antibodies as imaging agents, diagnostics and therapeutics are also provided. Dual-nuclear and fluorescently labeled or singly fluorescently labeled contrast agents promise the advantage of molecularly-guided surgical resection via surgical field near-infrared fluorescence (NIRF) imaging following (in the case of dual labeled agents) nuclear imaging for general localization. Currently, nodal staging of most cancers is performed following lymph node (LN) biopsy and dissection for subsequent pathological examination.


Intellectual Property Status

Issued U.S. Patent 9,790,274

Available for licensing.


Associated Publications

J Nucl Med. 2012 Sep;53(9):1427-37. doi: 10.2967/jnumed.112.106302. Epub 2012 Aug 7.

DOI: 10.2967/jnumed.112.106302


Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
For Information, Contact:
Christine Flynn
Associate Director, Licensing and New Venture Development
University of Texas Health Science Center At Houston
Barrett Harvey
Eva Sevick
Kenneth Pinkston
Ali Azhdarinia
© 2022. All Rights Reserved. Powered by Inteum